Agilent Technologies Inc (A) Stock Price Today
Aura AI Summary
Key Stats
- $42.16BMarket Cap
- -Volume
- HealthSector
- $157.2052W High
- $110.2452W Low
- -Typical Hold Time
- $43.71BEnterprise Value
- 0.68%Div Yield
- -Trading Activity
Track Agilent Technologies Inc (A) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Agilent Technologies Inc has traded between a low of $110.24 and a high of $157.2, highlighting its annual price range. Buy and sell Agilent Technologies Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Most Recent News
Inovio advances DNA medicine pipeline with FDA review of INO-3107 and $18.3M funding secured
Inovio Pharmaceuticals is progressing its DNA medicine pipeline with its lead candidate INO-3107 for Recurrent Respiratory Papillomatosis under FDA accelerated review, targeting a decision by October 30, 2026. The company raised $18.3 million in fund...
Life360 director Morin Brit sells 15,582 shares for $1 million
Morin Brit, a director at Life360, sold 15,582 shares of the company, generating $1 million from the transaction. This sale may indicate a personal financial decision or portfolio adjustment by the director. Investors might watch for any further insi...
AbCellera's stock jumps after successful menopause drug trial and CFO insider buying.
AbCellera Biologics announced positive Phase 2 trial results for its experimental menopause drug ABCL635, which significantly reduced hot flash frequency by 83%. The stock surged 33.19% to a 52-week high of $11.32, boosting the company's market cap t...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.